Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease
Pediatric Blood & Cancer · 2026-01 · 73 (1)
DOI: 10.1002/pbc.32125 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 21.10.2025. Verfasst von Destiny Uwaezuoke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA.
- Children's Health, Dallas, Texas, USA.
ORCID-Profile: Destiny Uwaezuoke, Jessica Garcia
Zitieren
APA
Uwaezuoke, D., Pham, A., & Garcia, J. (2026). Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease. Pediatric Blood & Cancer, 73(1). https://doi.org/10.1002/pbc.32125
Vancouver
Uwaezuoke D, Pham A, Garcia J. Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease. Pediatric Blood & Cancer. 2026;73(1). doi:10.1002/pbc.32125
BibTeX
@article{Uwaezuoke2026,
author = {Uwaezuoke, Destiny and Pham, An and Garcia, Jessica},
title = {Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {1},
doi = {10.1002/pbc.32125}
}
EUVIMED